Posted by Michael Wonder on 26 Sep 2022
Botanix submission of FDA new drug application for sofpironium bromide
26 September 2022 - Submission follows the results from the Cardigan (Phase 3) clinical studies which were positive and highly statistically significant.
Botanix Pharmaceuticals is pleased to announce the submission of a new drug application to the US FDA for approval of sofpironium bromide for patients with severe primary axillary hyperhidrosis.
